Roivant Sciences Ltd. Common Shares (ROIV) Stock
Key stats
- Market cap
- $30.32B
- Price / Earnings ratio
- -86.7x
- EPS (TTM)
- -$0.46
- Volume
- Loading
- 52-week high
- $42.50
- 52-week low
- $19.96
Source: third-party data provider, as of November 13, 2026
Compare with ROIV
Recent news

Roivant Sciences' Brepocitinib Delivers Positive Phase III Uveitis Results
Roivant Sciences' Brepocitinib Delivers Positive Phase III Uveitis Results
ROIV

IMVT, ROIV Stocks Slide As Argenx Sjögren’s Trial Failure Hits Drug Class
IMVT, ROIV Stocks Slide As Argenx Sjögren’s Trial Failure Hits Drug Class
ROIV

Roivant Sciences Targets LISRAYA Launch, Key Pipeline Readouts in Next 12 Months
Roivant Sciences Targets LISRAYA Launch, Key Pipeline Readouts in Next 12 Months
ROIV

Why Did DELL, ROIV, SHEL Stocks Surge To 52-Week Highs Today?
Why Did DELL, ROIV, SHEL Stocks Surge To 52-Week Highs Today?
ROIV
News tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 68.03
- MACD 12/26/9
- 1.16
- EMA 9 of MACD
- 0.53
- MACD histogram
- 0.63
- SMA 50
- $37.09
- Price above SMA 50
- EMA 50
- $36.81
- Price above EMA 50
- SMA 200
- $32.13
- Price above SMA 200
- EMA 200
- $31.73
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 7 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2026Earnings
No data available
Source: third-party data provider
Latest news

Roivant Sciences' Brepocitinib Delivers Positive Phase III Uveitis Results
Roivant Sciences' Brepocitinib Delivers Positive Phase III Uveitis Results
ROIV

IMVT, ROIV Stocks Slide As Argenx Sjögren’s Trial Failure Hits Drug Class
IMVT, ROIV Stocks Slide As Argenx Sjögren’s Trial Failure Hits Drug Class
ROIV

Roivant Sciences Targets LISRAYA Launch, Key Pipeline Readouts in Next 12 Months
Roivant Sciences Targets LISRAYA Launch, Key Pipeline Readouts in Next 12 Months
ROIV

Why Did DELL, ROIV, SHEL Stocks Surge To 52-Week Highs Today?
Why Did DELL, ROIV, SHEL Stocks Surge To 52-Week Highs Today?
ROIV

These 2 Biotech Stocks Hit Record Highs Today – What’s Driving The Rallies?
These 2 Biotech Stocks Hit Record Highs Today – What’s Driving The Rallies?
ROIV

Biotech Stocks, With 'Blowout' And 'Bull Case' Results, Rocket To Record Highs
Biotech Stocks, With 'Blowout' And 'Bull Case' Results, Rocket To Record Highs
ROIV

Roivant's experimental lung disease drug meets goals in mid-stage study
Roivant's experimental lung disease drug meets goals in mid-stage study
ROIV

Roivant Sciences Wins FDA Approval for LISRAYA in Dermatomyositis, Launches Immediately
Roivant Sciences Wins FDA Approval for LISRAYA in Dermatomyositis, Launches Immediately
ROIV

Roivant, Priovant launch newly approved rare disease drug Lisraya at $35,000 a month
Roivant, Priovant launch newly approved rare disease drug Lisraya at $35,000 a month
ROIV

US FDA approves Roivant-Priovant's skin and muscle disease drug
US FDA approves Roivant-Priovant's skin and muscle disease drug
ROIV
News tone: automated (AI) classification of the article's content, not a price prediction.
About Roivant Sciences Ltd. Common Shares
No description available.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Matthew Gline | CEO & Director | 1984 |
| Dr. Eric Venker M.D., Pharm.D. | President & CEO of Immunovant | 1987 |
| Dr. Frank M. Torti M.B.A., M.D. | President & Vant Chair | 1979 |
| Mr. Richard Pulik | Chief Financial Officer | 1980 |
| Dr. Mayukh Sukhatme M.D. | President, Chief Investment Officer & Director | 1976 |
| Ms. Jennifer Humes | Chief Accounting Officer | 1981 |
| Mr. Ian Rosenblum | Chief Information Officer | — |
| Mr. Sam Kaplan | General Counsel | — |
| Ms. Kelly Graff | Head of People | — |
| Mr. Alex Gasner | Executive Vice President of Roivant Health | — |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 68.03
- MACD 12/26/9
- 1.16
- EMA 9 of MACD
- 0.53
- MACD histogram
- 0.63
- SMA 50
- $37.09
- Price above SMA 50
- EMA 50
- $36.81
- Price above EMA 50
- SMA 200
- $32.13
- Price above SMA 200
- EMA 200
- $31.73
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
7 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $46.00
- Average
- $51.33
- High
- $56.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | -17.9 | +13.4 | ||||||||||
| 2022 | -29.9 | -12.2 | -22.1 | -23.8 | +15.3 | +0.7 | -10.0 | -3.3 | -9.6 | +53.0 | +1.1 | +37.8 |
| 2023 | +16.1 | -5.3 | -6.8 | +15.5 | +5.5 | +7.8 | +22.7 | -3.0 | +0.0 | -17.9 | +5.5 | +14.0 |
| 2024 | -11.9 | +13.8 | -10.5 | +4.5 | -7.6 | -2.7 | +0.2 | +15.2 | -2.0 | +1.6 | +8.8 | -5.2 |
| 2025 | -7.9 | +0.4 | -0.8 | +18.0 | -5.1 | +0.9 | +3.8 | +5.5 | +22.1 | +26.9 | +6.2 | +7.3 |
| 2026 | -1.4 | +31.9 | -1.4 | +2.5 | +7.8 | +21.7 | -3.2 | +4.0 | +5.9 | +4.0 | +16.6 |



